Current Agency Expectations for Approval for Biosimilars

Biosimilars are a generally new subset of biopharmaceuticals, with the biotechnology business eventually developing to such an extent that off-patent nonexclusive compose items progressively will enter real markets. Up so far , quite 20 biosimilars for a group number of reference items are affirmed in real markets, principally the ecu Union. Just two items are formally endorsed as biosimilars within the us . The parent field of biopharmaceuticals itself keeps on displaying a poor supporting framework of knowledge assets. Those biopharmaceutical and biosimilar data assets that do exist for the foremost part are restricted in number, assorted variety, and advancement.

  • Drug safety of biosimilars products
  • Regulatory aspects
  • Regulatory affairs and IPR of biosimilars products

Related Conference of Current Agency Expectations for Approval for Biosimilars

December 05-06, 2023

2nd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
February 01-02, 2024

37th World Congress on Pharmacology

Dubai, UAE
February 22-23, 2024

34th Annual European Pharma Congress

Zurich, Switzerland
April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France

Current Agency Expectations for Approval for Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in